Hypertension:老年高血压患者严格控制血压可增加脑血流量

2013-05-27 Hypertension dxy

研究证实老年人血压控制在150/90mmHg可减少卒中和心肌梗死风险,改善认知功能以及放缓或逆转脑血流量(CBF,cerebral blood flow )下降。有学者认为降压药物导致的低血压对老年人造成的危害大于高血压如低灌注导致晕厥、摔倒以及有可能加速萎缩和脑白质疏松。认知功能下降与CBF减少有关。预防CBF降低可减少老年高血压患者的认知障碍和情绪障碍。然而降压治疗对CBF的影响并不清楚。研究

研究证实老年人血压控制在150/90mmHg可减少卒中和心肌梗死风险,改善认知功能以及放缓或逆转脑血流量(CBF,cerebral blood flow )下降。有学者认为降压药物导致的低血压对老年人造成的危害大于高血压如低灌注导致晕厥、摔倒以及有可能加速萎缩和脑白质疏松。认知功能下降与CBF减少有关。预防CBF降低可减少老年高血压患者的认知障碍和情绪障碍。然而降压治疗对CBF的影响并不清楚。研究人员通过一项随机对照研究比较老年高血压患者严格控制血压和一般血压控制的对CBF的影响。

研究对象为37例大于70岁(75±4岁)的老年患者,有收缩性高血压病史(SBP>150 mm Hg),服用1种或未服用降压药物。将受试者随机分为接受严格降压(目标血压<130/80 mm Hg))或一般降压(目标血压<140/85 mm Hg)治疗12周,每两周随访一次。分别在研究开始和治疗12周后采用3T的动脉血质子自旋标记MRI评估CBF以及行24小时动态血压检查。

两组间基线血压(动态或门诊)和基线的灰质CBF无明显差异。经过治疗后,两组血压明显降低,但严格控压组血压降低更多(26/17 比 15/5 mm Hg; P<0.01)。同时测定的灰质CBF显示严格控压组明显增加(7±11 mL/min每100 g; P=0.013),而一般降压组受试者灰质CBF未发生变化((?3±9 mL/min 每100g; P=0.23)。

老年高血压患者严格控制血压较一般控制血压相比,前者可增加CBF。这一研究表明老年高血压患者的CBF自动调节曲线向右下移动,但随着血压降低这一过程是可逆的。

未来的研究需进一步确定是否严格控制血压白质也会产生类似的结果,老年患者严格控制血压后是否老年痴呆和认知能力下降的风险降低。

Intensive blood pressure lowering increases cerebral blood flow in older subjects with hypertension.
Abstract
Hypertension is associated with reduced cerebral blood flow (CBF). Intensive (<130/80 mm Hg) blood pressure (BP) lowering in older people might give greater reduction in cardiovascular risk, but there are concerns that this might produce hypoperfusion which may precipitate falls and possibly stroke. We determined the effect of intensive compared with usual BP lowering on CBF in hypertensive older subjects. Individuals aged >70 years with a history of systolic hypertension on 1 or no BP lowering drugs were recruited from primary care (n=37; age, 75±4 years; systolic BP, >150 mm Hg) and randomized to receive intensive (target BP, <130/80 mm Hg) or usual (target BP, <140/85 mm Hg) BP lowering for 12 weeks, with reviews every 2 weeks. CBF, determined using 3T arterial spin labeling MRI, and 24-hour ambulatory BP were performed at baseline and after 12 weeks of treatment. Baseline BP (ambulatory or in clinic) and baseline gray matter CBF were not significantly different between the groups. After treatment, BP was reduced significantly in both groups but fell more in the intensive group (26/17 versus 15/5 mm Hg; P<0.01). Over the same period, gray matter CBF increased significantly in the intensive group (7±11 mL/min per 100 g; P=0.013) but was unchanged in the usual BP target group (-3±9 mL/min per 100 g; P=0.23); P<0.01 for comparison. Intensive BP lowering in older people with hypertension increases CBF, compared with BP lowering to usual target. These findings suggest hypertension in older people shifts the autoregulatory CBF curve rightward and downward and is reversible with BP lowering.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1988316, encodeId=c46a198831667, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 28 05:40:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075884, encodeId=f2ee20e588479, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jun 05 00:40:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725512, encodeId=e4601e2551264, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 03 02:40:00 CST 2013, time=2013-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038465, encodeId=568f203846539, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 11 11:40:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042250, encodeId=cf1b204225020, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat Nov 02 06:40:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448119, encodeId=8e6f1448119cf, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478893, encodeId=69ce14e889362, content=<a href='/topic/show?id=5de08024597' target=_blank style='color:#2F92EE;'>#老年高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80245, encryptionId=5de08024597, topicName=老年高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87307462084, createdName=124985dbm08(暂无昵称), createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501021, encodeId=58fc150102106, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1988316, encodeId=c46a198831667, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 28 05:40:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075884, encodeId=f2ee20e588479, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jun 05 00:40:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725512, encodeId=e4601e2551264, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 03 02:40:00 CST 2013, time=2013-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038465, encodeId=568f203846539, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 11 11:40:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042250, encodeId=cf1b204225020, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat Nov 02 06:40:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448119, encodeId=8e6f1448119cf, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478893, encodeId=69ce14e889362, content=<a href='/topic/show?id=5de08024597' target=_blank style='color:#2F92EE;'>#老年高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80245, encryptionId=5de08024597, topicName=老年高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87307462084, createdName=124985dbm08(暂无昵称), createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501021, encodeId=58fc150102106, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1988316, encodeId=c46a198831667, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 28 05:40:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075884, encodeId=f2ee20e588479, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jun 05 00:40:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725512, encodeId=e4601e2551264, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 03 02:40:00 CST 2013, time=2013-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038465, encodeId=568f203846539, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 11 11:40:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042250, encodeId=cf1b204225020, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat Nov 02 06:40:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448119, encodeId=8e6f1448119cf, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478893, encodeId=69ce14e889362, content=<a href='/topic/show?id=5de08024597' target=_blank style='color:#2F92EE;'>#老年高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80245, encryptionId=5de08024597, topicName=老年高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87307462084, createdName=124985dbm08(暂无昵称), createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501021, encodeId=58fc150102106, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]
    2013-08-03 feather89
  4. [GetPortalCommentsPageByObjectIdResponse(id=1988316, encodeId=c46a198831667, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 28 05:40:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075884, encodeId=f2ee20e588479, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jun 05 00:40:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725512, encodeId=e4601e2551264, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 03 02:40:00 CST 2013, time=2013-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038465, encodeId=568f203846539, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 11 11:40:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042250, encodeId=cf1b204225020, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat Nov 02 06:40:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448119, encodeId=8e6f1448119cf, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478893, encodeId=69ce14e889362, content=<a href='/topic/show?id=5de08024597' target=_blank style='color:#2F92EE;'>#老年高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80245, encryptionId=5de08024597, topicName=老年高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87307462084, createdName=124985dbm08(暂无昵称), createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501021, encodeId=58fc150102106, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1988316, encodeId=c46a198831667, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 28 05:40:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075884, encodeId=f2ee20e588479, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jun 05 00:40:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725512, encodeId=e4601e2551264, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 03 02:40:00 CST 2013, time=2013-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038465, encodeId=568f203846539, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 11 11:40:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042250, encodeId=cf1b204225020, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat Nov 02 06:40:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448119, encodeId=8e6f1448119cf, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478893, encodeId=69ce14e889362, content=<a href='/topic/show?id=5de08024597' target=_blank style='color:#2F92EE;'>#老年高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80245, encryptionId=5de08024597, topicName=老年高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87307462084, createdName=124985dbm08(暂无昵称), createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501021, encodeId=58fc150102106, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1988316, encodeId=c46a198831667, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 28 05:40:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075884, encodeId=f2ee20e588479, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jun 05 00:40:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725512, encodeId=e4601e2551264, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 03 02:40:00 CST 2013, time=2013-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038465, encodeId=568f203846539, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 11 11:40:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042250, encodeId=cf1b204225020, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat Nov 02 06:40:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448119, encodeId=8e6f1448119cf, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478893, encodeId=69ce14e889362, content=<a href='/topic/show?id=5de08024597' target=_blank style='color:#2F92EE;'>#老年高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80245, encryptionId=5de08024597, topicName=老年高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87307462084, createdName=124985dbm08(暂无昵称), createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501021, encodeId=58fc150102106, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1988316, encodeId=c46a198831667, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 28 05:40:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075884, encodeId=f2ee20e588479, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jun 05 00:40:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725512, encodeId=e4601e2551264, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 03 02:40:00 CST 2013, time=2013-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038465, encodeId=568f203846539, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 11 11:40:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042250, encodeId=cf1b204225020, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat Nov 02 06:40:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448119, encodeId=8e6f1448119cf, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478893, encodeId=69ce14e889362, content=<a href='/topic/show?id=5de08024597' target=_blank style='color:#2F92EE;'>#老年高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80245, encryptionId=5de08024597, topicName=老年高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87307462084, createdName=124985dbm08(暂无昵称), createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501021, encodeId=58fc150102106, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1988316, encodeId=c46a198831667, content=<a href='/topic/show?id=5a5c56e3945' target=_blank style='color:#2F92EE;'>#控制血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56739, encryptionId=5a5c56e3945, topicName=控制血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6f7a159, createdName=3631173, createdTime=Sun Jul 28 05:40:00 CST 2013, time=2013-07-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2075884, encodeId=f2ee20e588479, content=<a href='/topic/show?id=b208891e986' target=_blank style='color:#2F92EE;'>#血流量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89179, encryptionId=b208891e986, topicName=血流量)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a691420, createdName=30397604, createdTime=Wed Jun 05 00:40:00 CST 2013, time=2013-06-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1725512, encodeId=e4601e2551264, content=<a href='/topic/show?id=986913980dd' target=_blank style='color:#2F92EE;'>#PE#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13980, encryptionId=986913980dd, topicName=PE)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f06c33759375, createdName=feather89, createdTime=Sat Aug 03 02:40:00 CST 2013, time=2013-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038465, encodeId=568f203846539, content=<a href='/topic/show?id=b45d1e274e8' target=_blank style='color:#2F92EE;'>#TENS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17274, encryptionId=b45d1e274e8, topicName=TENS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3b172500206, createdName=12498ebem19暂无昵称, createdTime=Sun Aug 11 11:40:00 CST 2013, time=2013-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2042250, encodeId=cf1b204225020, content=<a href='/topic/show?id=754b8508329' target=_blank style='color:#2F92EE;'>#脑血流#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=85083, encryptionId=754b8508329, topicName=脑血流)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b191324, createdName=marongnuan, createdTime=Sat Nov 02 06:40:00 CST 2013, time=2013-11-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1448119, encodeId=8e6f1448119cf, content=<a href='/topic/show?id=5a9c102681f2' target=_blank style='color:#2F92EE;'>#高血压患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=102681, encryptionId=5a9c102681f2, topicName=高血压患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b4665409655, createdName=维他命, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478893, encodeId=69ce14e889362, content=<a href='/topic/show?id=5de08024597' target=_blank style='color:#2F92EE;'>#老年高血压#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80245, encryptionId=5de08024597, topicName=老年高血压)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=87307462084, createdName=124985dbm08(暂无昵称), createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1501021, encodeId=58fc150102106, content=<a href='/topic/show?id=f2db9238f9' target=_blank style='color:#2F92EE;'>#Hypertension#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9238, encryptionId=f2db9238f9, topicName=Hypertension)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=11ff9497046, createdName=jambiya, createdTime=Wed May 29 05:40:00 CST 2013, time=2013-05-29, status=1, ipAttribution=)]

相关资讯

Lancet:利尿剂并不是对肥胖高血压患者合理的治疗方案

众所周知,肥胖会导致高血压,相反的,高血压也会导致肥胖,因此,这两种障碍可能同时存在。然而,除了高血压所影响的靶器官外,肥胖还会影响血流动力学、 神经内分泌和代谢过程。因为多余的脂肪组织需要更多的心输出量来满足代谢需求,所以无论动脉压力如何,与瘦的患者相比,肥胖的患者血管阻力更低,而血管阻 力又是血管病变的标志之一,因为其在肥胖患者中较低,所以肥胖能对高血压病变的靶器官带来部分保护作用。这即是所谓

PAS2013:超重儿将早面临高血压风险

  华盛顿——在美国儿科学术团体(PAS)2013年会上,明尼苏达州布卢明顿HealthPartners教育研究所的Emily D. Parker博士报告称,在生长发育过程中出现超重或肥胖的儿童,早在3~5岁时就有可能罹患高血压。   这项研究分析了59,638名年龄介于3~17岁的儿童的体重和血压变化趋势。这些儿童数据来自加利福利亚洲、科罗拉多州和明尼苏达州的3个大型保险数据库2007~201

Circulation:未控制高血压仍为急性主动脉夹层显著危险因素

     英国一项研究表明,未控制高血压仍为急性主动脉夹层的最显著可治疗危险因素。论文4月18日在线发表于《循环》(Circulation)。   急性主动脉夹层是一种可预防的致命性疾病,但目前尚无前瞻性人群研究对危险因素、预防策略和未来临床服务计划加以明确。此项研究在92728例受试者中对急性主动脉夹层的发病率和转归进行了前瞻性评估。   结果显示,在伴有173例次急性主动脉事件的154例

JAMA:常用高血压药物能造福更多心衰患者

2012年11月28日 --瑞典卡罗琳斯卡医学院一项新研究表明常用来治疗心脏衰竭和高血压的药物可能具有更广泛的应用范围,或许可以用来治疗所谓的HFPEF-A型心脏衰竭。到现在为止HFPEF-A型心脏衰竭是无法治疗的。 相关研究成果发表在科学杂志JAMA上,结果表明一组HFPEF患者使用这些药物后死亡率下降。心脏衰竭影响总人口的3%,并以两种形式存在:收缩能力下降和心脏舒张能力下降。前者影响较年轻

Hypertension:合并隐匿性高血压的糖尿病患者需进一步降压治疗

尽管大家对糖尿病患者隐匿性高血压(masked hypertension)的特点已经很清楚。然而对于这些患者临床上进行降压治疗的意义尚未完全清楚。IDACO研究(The current International Database on Ambulatory Blood Pressure Monitoring in Relation to Cardiovascular Outcomes )中的受试

JAMA:高血压加重遗传易感AD患者的脑内淀粉样蛋白沉积

日前发表于国际权威杂志JAMA的一项研究表明,高血压合并阿尔茨海默病的遗传风险因素会导致认知功能正常的成人脑淀粉蛋白沉积增加。 研究者美国达拉斯德克萨斯大学Karen Rodrigue博士及其同事的研究显示,与仅有一项阿尔茨海默病风险因子或无风险因子的患者相比,高血压合并至少一项阿尔茨海默病遗传风险因素(载脂蛋白E ?4等位基因)的患者表现出更多的β-淀粉蛋白(Αβ)积累症状。 脑部β淀粉样蛋